FDA Grants Fast Track Designation to UV1 Vaccine Combo in Unresectable Mesothelioma
February 6th 2024Data from the phase 2 NIPU trial support the FDA’s fast track designation for UV1 in combination with nivolumab and ipilimumab as a treatment for those with unresectable pleural malignant mesothelioma.